… with caution, because high mitotic rates yield tetrasomy during the M phase of the cell cycle.
… T4 stage to sT3; N staging and M staging remained unchanged. The corresponding stages …

BACKGROUND & AIMS: Cholangiocarcinoma is a heterogeneous disease with a poor
outcome that accounts for 5%−10% of primary liver cancers. We characterized its genomic and …

… The slides were reviewed by three independent pathologists (M. Komuta, M. Kojiro, and T. …
Expression of oncostatin M and its receptors in normal and cirrhotic human liver. J Hepatol …

… These are lesions best described by the LIRADS category LR-M, probably or definitely
malignant but not specific for HCC. The challenges associated with imaging cHCCCCA raise two …

Objective Keratin (K)19, a biliary/hepatic progenitor cell (HPC) marker, is expressed in a
subset of hepatocellular carcinomas (HCC) with poor prognosis. The underlying mechanisms …

… The slides were reviewed by two independent pathologists (M. Komuta and T. Roskams).
Immunoreactivity was considered positive if more than 1% of tumor cells were stained in the …

Background and Aims The benefit of rapid on-site evaluation (ROSE) on the diagnostic
accuracy of endoscopic ultrasound–guided fine-needle biopsy (EUS-FNB) has never been …

The farnesoid X receptor (FXR) is a nuclear bile acid receptor involved in bile acid
homeostasis, hepatic and intestinal inflammation, liver fibrosis, and cardiovascular disease. We …

The liver is located in a toxic-rich environment, and consequently is required to tolerate
frequent exposure to toxins. In addition, the liver can be affected by a wide variety of toxins, …

Advanced liver fibrosis in nonalcoholic steatohepatitis (NASH) is often accompanied by a
reduction in hepatic fat to the point of complete fat loss (burnt‐out NASH), but the mechanisms …